Copied


Eli Lilly (LLY) Stock Price Prediction: Lilly holds a premium setup as analysts lean higher, but short-term flow is softer

Tony Kim   Nov 18, 2026 16:29 0 Min Read


What changed

Eli Lilly (LLY) is still priced like a quality-growth leader, but the tape is not clean in the very near term. The stock is at $1,405.13, down 1.66% on the day, with a 24-hour range of $1,432.27 to $1,400.03. That puts shares just below the 20-day average at $1,411.31 and the 7-day average at $1,427.15, while still well above the 50-day average at $1,299.47.

The bigger fundamental story remains intact. On October 29, Lilly reported third-quarter 2026 revenue of $24.4 billion, up 39% year over year, and raised its full-year 2026 revenue guidance midpoint by $5.5 billion to a range of $91.0 billion to $92.0 billion. The company also lifted underlying non-GAAP EPS guidance at the midpoint. That is the core reason the stock keeps attracting higher price targets.

Analyst targets are still drifting higher

The latest broker notes point in the same direction, even if they do not remove short-term volatility. Barclays raised its target to $1,550 from $1,400 and kept an overweight rating. RBC Capital reiterated Outperform and set a $1,600 target, while Jefferies lifted its target to $1,700 from $1,610 and maintained a Buy rating.

Those targets matter because they frame the market’s willingness to pay up for Lilly’s pipeline and execution. RBC also highlighted the company’s Innovation Day on December 7 as a strategically important event for showing growth beyond obesity, which gives investors a known date to watch. The current price is below all three of those published targets, but that does not mean the stock is automatically cheap; it simply means analysts still see room if the growth narrative stays intact.

Technical setup: constructive, but not acceleration yet

The moving-average structure is still bullish, with price above the 50-day, 20-day and 12-day averages, and only slightly below the 7-day average. That usually describes a stock digesting gains rather than breaking trend.

Momentum is mixed. Daily RSI is 57.02, which sits in neutral territory, so there is no obvious overbought or oversold signal. MACD is flat relative to its signal line, with a histogram of 0.0000, which is consistent with stalled momentum rather than a fresh breakout. Stochastic readings at 45.69 for %K and 36.55 for %D also point to a mid-range setup rather than an exhausted move.

Volume adds an important layer. The stock is trading on 0.39x of its 5-day average volume, which suggests a low-volume pullback rather than a disorderly unwind. In practical terms, that is constructive if buyers defend the nearby support band.

Levels that matter

Immediate support is $1,392.68, with stronger support at $1,380.24. On the upside, immediate resistance sits at $1,424.92, with stronger resistance at $1,444.72. The Bollinger middle band is $1,411.31, basically aligned with the 20-day average, so that area is the first pivot the market needs to reclaim decisively.

ATR(14) is $37.57, which tells you the stock can still move meaningfully in a normal session. That matters because a break below the support band could widen quickly, while a recovery through $1,425 would put the stock back on track toward the upper end of the recent range.

Derivatives positioning leans cautious

Binance perpetual futures data is softer than the equity research tone. Funding is neutral at 0.0000%, open interest is down 0.80% in 24 hours to 2,354.45 contracts, and the daily open interest value is $3.22 million. That looks like reduced speculative commitment rather than a crowded directional bet.

The long/short split also leans short. Binance global accounts show 44.0% long and 56.0% short, while top-trader accounts are even more skewed at 42.0% long and 58.0% short. The taker buy/sell ratio of 0.8908, combined with the reported buy and sell volumes, points to aggressive selling pressure in the derivatives market. That does not override the equity trend, but it does suggest momentum traders are not uniformly chasing the name higher right now.

What would change the setup

Bullish continuation would require Lilly to reclaim the $1,424.92 resistance area and hold above the 20-day average, which would reopen a move toward $1,444.72 and then the upper Bollinger band at $1,469.19. A stronger catalyst would be any confirmation that the company’s growth beyond obesity is landing with investors, especially around the December 7 Innovation Day.

The downside case is cleaner to define than the upside. A break below $1,392.68 would expose $1,380.24, and losing that area would weaken the current bullish moving-average structure. If that happens, the stock would likely spend more time repairing the trend rather than extending the premium multiple.


Read More